Cingulate Inc (CING)

Currency in USD
4.780
+0.310(+6.94%)
Closed·
4.960+0.180(+3.77%)
·
CING is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.4205.150
52 wk Range
3.20011.890
Key Statistics
Prev. Close
4.47
Open
4.45
Day's Range
4.42-5.15
52 wk Range
3.2-11.89
Volume
865.71K
Average Volume (3m)
535.98K
1-Year Change
30.2452%
Book Value / Share
1.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CING Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.902
Upside
+441.88%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cingulate Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.902
(+441.88% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy20.00+318.41%-Maintain26/05/2026
Roth/MKM
Buy14.00+192.89%16.00Maintain23/03/2026
Ascendiant Capital
Buy62.00+1,197.07%61.00Maintain22/08/2025

Earnings

Latest Release
14/05/2026
EPS / Forecast
-0.95 / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare CING to Peers and Sector

Metrics to compare
CING
Peers
Sector
Relationship
P/E Ratio
−2.3x−2.3x−0.5x
PEG Ratio
−0.05−0.040.00
Price/Book
3.4x1.9x2.6x
Price / LTM Sales
-1.4x3.1x
Upside (Analyst Target)
370.7%134.7%53.2%
Fair Value Upside
Unlock8.2%6.2%Unlock

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
431.65K3.52%1.93M
Other Institutional Investors
2.83M23.07%12.63M
Public Companies & Retail Investors
8.99M73.41%40.20M
Total
12.25M100.00%54.76M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Index Funds - Vanguard Total Stock Market ETF1.73%211,655946
Vanguard Index Funds - Vanguard Extended Market ETF0.75%91,715410

People Also Watch

1.3300
INHD
+0.76%
1.53
PEPG
+1.32%
5.770
CPIX
-1.70%
1.470
EZGO
-9.26%

FAQ

What Is the Cingulate (NASDAQ: CING) Share Price Today?

The Cingulate stock price today is 4.780 USD.

What Stock Exchange Does Cingulate (CING) Trade On?

Cingulate is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Cingulate?

The stock symbol (also called a 'ticker') for Cingulate is "CING."

What Is the Current Cingulate Market Capitalisation?

As of today, Cingulate (NASDAQ: CING) market cap is 59.340M USD.

What Is Cingulate's (CING) Earnings Per Share (TTM)?

The Cingulate EPS is currently -4.236 (Trailing Twelve Months).

Is CING a Buy or Sell From a Technical Analyst Perspective?

Based on today's Cingulate moving averages and other technical indicators, the daily buy/sell signal for CING stock is Sell.

How Many Times Has Cingulate Stock Split?

Cingulate has split 2 times. (See the CING stock split history page for full effective split date and price information.)

How Many Employees Does Cingulate Have?

Cingulate has 14 employees, based on their latest Companies House report.

What is the current trading status of Cingulate (NASDAQ: CING)?

As of 27/05/2026, Cingulate (CING) is trading at a share price of 4.780 USD, with a previous close of 4.470 USD. The stock has fluctuated within a day range of 4.420 USD to 5.150 USD, while its 52-week range spans from 3.200 USD to 11.890 USD.

What Is Cingulate (CING) Price Target According to Analysts?

The average 12-month price target for Cingulate is 25.902 USD, with a high estimate of 55 USD and a low estimate of 8 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +441.88% Upside potential.

What Is the CING Premarket Price?

CING's last pre-market stock price is 4.450 USD. The pre-market share volume is 39,670.000, and the stock has decreased by -0.020, or -0.450%.

What Is the CING After Hours Price?

CING's last after hours stock price is 4.960 USD, the stock has decreased by 0.180, or 3.770%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.